The "5th Annual Circulating Biomarkers and Extracellular Vesicles Europe 2023" conference has been added to ResearchAndMarkets.com's offering. The Circulating Biomarkers & Extracellular Vesicles...

The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors The...

Vial, a global tech-first CRO providing next-generation clinical trial management services, announced it will be a sponsor and exhibitor at the 2023 BIO International Convention in Boston, MA,...

Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on...

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in...

Physician-scientists will present expansive new cancer research, including 33 accepted abstracts NEW BRUNSWICK, N.J., May 25, 2023 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey and...

The company serves as a model for businesses that aim to support veterans, achieving a 240+% increase in veteran hires since 2020 and expanding initiatives to extend assistance in 2023 and beyond...

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in...

BTX-9341 demonstrated potent degradation of CDK4/6 and tumor growth regression in resistant cells in preclinical breast cancer models, along with robust blood brain barrier penetration SOS1...

Vorasidenib data from the INDIGO Phase 3 trial adds to the body of evidence on the impact of targeting the IDH mutation in cancer with the first major advancement in low-grade glioma in 23 years...